Key Performance Indicators
PRIMARY
Global Health TTD HR
0.81
95% CI: 0.62–1.1
19% risk reduction in QOL deterioration
Pain Severity TTD HR
0.77
95% CI: 0.57–1.05
Trend favoring Ribociclib
Median TTD (Pain)
42.7 mo
vs 35.9 mo (Placebo)
+6.8 months delay in pain worsening
Emotional Func. HR
0.76
95% CI: 0.57–1.01
Strong trend favoring Ribociclib
1
Hazard Ratios: Time to Definitive Deterioration (TTD)
Hazard ratios < 1.0 indicate a favorable delay in deterioration for the Ribociclib arm. While some CIs cross 1.0, the consistent leftward shift suggests a protective effect across domains.
2
Extension of Time to Deterioration (Months)
Ribociclib consistently extends the time until patients experience a definitive 10% deterioration in quality of life metrics compared to placebo.
3
Symptom Stability: Baseline vs. Cycle 15
Despite the addition of a CDK4/6 inhibitor, symptom scores (lower is better) remained stable or improved slightly over 15 cycles of treatment in the Ribociclib arm.
4
Global Health Status Score Over Time
Global Health Status scores improved from baseline in both arms and were maintained throughout treatment, indicating no detrimental effect of Ribociclib on overall QOL.
Editorial Conclusion
“Ribociclib plus fulvestrant significantly delays the deterioration of quality of life compared to placebo, effectively decoupling increased treatment intensity from increased patient burden.”
Global Health Status deterioration was delayed (HR 0.81).
Pain progression was notably slower in the Ribociclib arm (+6.8 months median delay).
Symptom scores for fatigue, nausea, and diarrhea remained stable relative to baseline.
Clinical Implication
Clinicians can prescribe this combination with confidence that the survival benefits do not come at the cost of accelerated quality of life decline.
Reference Data & Sources
Complete Data Table
| Metric | Group | Value | Unit | Source |
|---|---|---|---|---|
| Global Health Status TTD (≥10%) | Ribociclib vs Placebo | 0.81 (0.62–1.1) | Hazard Ratio | Abstract/Results |
| Pain Severity Index TTD (≥10%) | Ribociclib vs Placebo | 0.77 (0.57–1.05) | Hazard Ratio | Results |
| Median TTD Global Health | Ribociclib | 35.9 | Months | Figure 2a |
| Median TTD Global Health | Placebo | 33.1 | Months | Figure 2a |
Abbreviations
HR = Hazard Ratio · TTD = Time to Deterioration · QOL = Quality of Life · BPI-SF = Brief Pain Inventory-Short Form · EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
Source
Fasching et al. The Breast. 2020;54:148-154
DOI: 10.1016/j.breast.2020.09.008
DOI: 10.1016/j.breast.2020.09.008
Limitations
No post-progression PRO assessments were performed. Differences in HRQOL deterioration were not statistically significant (CIs crossed 1) for some subscales. Descriptive statistics only for longitudinal changes due to difficulty interpreting subscales.